Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • (-)-Arctigenin: Precision MEK1 and iNOS Inhibitor for NF-...

    2026-01-13

    (-)-Arctigenin: Precision MEK1 and iNOS Inhibitor for NF-κB Pathway Research

    Executive Summary: (-)-Arctigenin is a bioactive small molecule natural product exhibiting potent inhibition of MEK1 (IC50 0.5 nM) and iNOS expression (IC50 10 nM), with applications in anti-inflammatory, antiviral, and neuroprotection research. It suppresses NF-κB signaling by blocking IκBα phosphorylation and p65 nuclear translocation, and inhibits HIV-1 replication in vitro. The compound is insoluble in water or ethanol but highly soluble in DMSO (≥17.2 mg/mL), and is supplied at >98% purity by APExBIO. Mechanistic studies reveal direct relevance to breast cancer cell invasion and tumor microenvironment modulation via targeted pathway inhibition (Li et al., 2022; APExBIO).

    Biological Rationale

    The NF-κB and MAPK/ERK signaling pathways are central to inflammatory and tumorigenic processes. Tumor-associated macrophages (TAMs) release extracellular vesicles (EVs) containing microRNAs (e.g., miR-660) that activate NF-κB p65, promoting cancer cell invasion and metastasis (Li et al., 2022). Agents that suppress iNOS and MEK1—key regulators in these pathways—offer translational value for cancer and immunology research. (-)-Arctigenin, a lignan isolated from Arctium lappa, has emerged as a dual-action inhibitor for these targets (APExBIO).

    Mechanism of Action of (-)-Arctigenin

    (-)-Arctigenin exerts its primary effects by inhibiting two major molecular targets:

    • iNOS suppression: Inhibits LPS-induced iNOS expression by blocking IκBα phosphorylation and preventing p65 NF-κB nuclear translocation (IC50 10 nM) (APExBIO).
    • MEK1 inhibition: Potently blocks mitogen-activated protein kinase kinase 1 (MEK1/MKK1) with IC50 of 0.5 nM, attenuating downstream MAPK/ERK signaling (Related Article).
    • Kainate receptor binding: Directly binds kainate receptors, mediating neuroprotective effects in neuronal models (APExBIO).
    • Antiviral activity: Inhibits in vitro HIV-1 replication at micromolar concentrations (APExBIO).

    By targeting these pathways, (-)-Arctigenin disrupts key steps in cancer cell survival, migration, and immune evasion (see comparison: detailed mechanism mapping).

    Evidence & Benchmarks

    • Suppresses LPS-induced iNOS expression in macrophages (IC50 = 10 nM) via inhibition of IκBα phosphorylation and p65 nuclear import (APExBIO QC Data).
    • Inhibits MEK1 (MKK1) kinase activity in vitro (IC50 = 0.5 nM), validated by HPLC and NMR purity metrics (>98%) (APExBIO).
    • Reduces NF-κB p65 signaling, a key driver of tumor microenvironment remodeling in breast cancer models (Li et al., 2022).
    • Inhibits HIV-1 replication in cellular assays at concentrations ≤10 μM (APExBIO).
    • Demonstrates neuroprotective effects through kainate receptor binding (APExBIO).

    Applications, Limits & Misconceptions

    Core Applications:

    • Dissection of NF-κB and MAPK/ERK signaling in cancer, inflammation, and neurobiology.
    • Modeling tumor microenvironment modulation, particularly in studies focused on breast cancer and TAMs (Li et al., 2022).
    • Antiviral mechanism research for HIV-1 and related viruses (APExBIO).
    • Cell-based assay optimization for viability, proliferation, and cytotoxicity endpoints (Optimizing Cell Assays: This article extends cell assay optimization by detailing pathway-specific benchmarks for (-)-Arctigenin).

    Common Pitfalls or Misconceptions

    • Not a pan-inhibitor: (-)-Arctigenin does not broadly suppress all kinases or transcription factors; its action is selective for MEK1 and iNOS pathways (APExBIO).
    • Solubility constraints: The compound is insoluble in water or ethanol—use DMSO (≥17.2 mg/mL) for stock solutions (APExBIO).
    • Not suitable for long-term solution storage: Stock solutions are unstable over extended periods; prepare fresh aliquots for each experiment (APExBIO).
    • No direct effect on non-NF-κB mediated pathways: Efficacy is reduced in cell types where iNOS/NF-κB signaling is not the primary driver (Precision Use-Cases: This guide clarifies limitations for off-pathway models).
    • In vivo translation: Potency and bioavailability in vivo may differ from in vitro results; animal model-specific optimization is required (Applied Strategies: This resource updates practical considerations for translational use).

    Workflow Integration & Parameters

    For routine use, (-)-Arctigenin (SKU N2399) is supplied as a >98% pure solid by APExBIO. Dissolve in DMSO at concentrations up to 17.2 mg/mL. Store powder at -20°C desiccated; avoid repeated freeze-thaw cycles. Do not store stock solutions long-term. For iNOS inhibition, use at 10–100 nM; for MEK1 inhibition, 0.5–10 nM is effective in most cell lines. Verify pathway inhibition by immunoblot for IκBα, p65, and ERK1/2 phosphorylation. Quality control includes HPLC, NMR, and MSDS documentation ((-)-Arctigenin product page).

    Conclusion & Outlook

    (-)-Arctigenin is a potent, selective inhibitor of iNOS and MEK1, with well-defined anti-inflammatory and antiviral activities. Its role in modulating NF-κB and MAPK/ERK pathways positions it as a model compound for dissecting tumor microenvironment dynamics and neuroprotection. Continued development of pathway-selective inhibitors like (-)-Arctigenin will support advances in targeted cancer and inflammation research. For further application-specific protocols and troubleshooting, see Applied Research with (-)-Arctigenin, which delivers advanced guidance for bench scientists.